tilarginine
Small moleculeexperimental
N-Methylarginine is an inhibitor of nitric oxide synthase. Chemically, it is a methyl derivative of the amino acid arginine. It is used as a biochemical tool in the study of physiological role of nitric oxide. — Wikipedia
Clinical trial activity
15 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Jul 1, 1999 (NCT00431665)
Timeline
Indications
Studied for
- Fibrosis · Phase 1
- Glomerulonephritis · Phase 1
- Healthy Volunteers · Phase 1
- Heart Failure · Phase 1
- Hypertension · Phase 1
- Insulin Resistance · Phase 1
- Liver Cirrhosis · Phase 1
- Obesity · Phase 1
- Ocular Physiological Phenomena · Phase 2
- Optic Disk · Phase 2
- Polycystic Kidney, Autosomal Dominant · Phase 1
- Regional Blood Flow · Phase 2
- Shock, Cardiogenic · Phase 3
Mechanism of action
- Nitric-oxide synthase, brainINHIBITOR
NOS1 inhibitor
- Nitric oxide synthaseINHIBITOR
Nitric oxide synthase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=N)NCCC[C@H](N)C(=O)O- Mol. weight
- 188.23 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL256147 ↗
- WikipediaMethylarginine ↗
- ChEMBLCHEMBL312870 ↗
- ChEMBLCHEMBL1256175 ↗
Also known as
- ano-1020
- ano-1020
- l-n(g)-mono-methylarginine acetate
- n(g)-monomethylarginine acetate
- ng-monomethyl-l-arginine
- ng-monomethyl-l-arginine
- n-monomethyl-l-arginine
- n-monomethyl-l-arginine
- targinine
- targinine
- tilarginine
- tilarginine
- tilarginine
- tilarginine acetate
- tilarginine acetate
- tilarginine acetate
- tilarginine acetate
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01860911 | Phase 1 | Apr 1, 2013 | American Diabetes Association, Mayo Clinic |
| NCT01617551 | N/A | Mar 1, 2012 | Aarhus University |
| NCT00914394 | N/A | Oct 1, 2010 | University of Vienna |
| NCT01070940 | Phase 1 | Feb 1, 2010 | Aarhus University |
| NCT00806741 | N/A | Sep 1, 2009 | University of Vienna |
| NCT00406731 | Phase 2 | Jan 1, 2008 | University of Vienna |
| NCT00344916 | Phase 1 | Jun 24, 2006 | Aarhus University |
| NCT00344734 | Phase 1 | Jun 24, 2006 | Aarhus University |
| NCT00345137 | Phase 1 | Jun 24, 2006 | Aarhus University |
| NCT00345150 | Phase 1 | Jun 24, 2006 | Aarhus University |
| NCT00708357 | Early Phase 1 (Phase 1) | May 1, 2005 | University of Vienna |
| NCT00112281 | Phase 3 | May 1, 2005 | Arginox Pharmaceuticals, New York University |
| NCT00431392 | Phase 2 | Sep 1, 2001 | University of Vienna |
| NCT00005107 | Phase 1 | Apr 11, 2000 | National Center for Research Resources (NCRR) |
| NCT00431665 | N/A | Jul 1, 1999 | University of Vienna |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aarhus University | Academic/Hospital | 6 | 6 | 2 | 2006 |
| University of Vienna | Academic/Hospital | 6 | 6 | 3 | 1999 |
| American Diabetes Association | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Arginox Pharmaceuticals | For profit | 1 | 1 | 1 | 2005 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2013 |
| National Center for Research Resources (NCRR) | Government | 1 | 1 | 1 | 2000 |
| New York University | Academic/Hospital | 1 | 0 | 1 | 2005 |
7 organizations
Page 1 / 1